KF

Katherine Fuh

Washington University in St. Louis

Affiliated withWashington University in St. Louis University of California San Francisco

Research Area

Cancer Research

Biography

Katherine Fuh has not added Biography.
If you are Katherine Fuh and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 1	Year
Publication title Cited by 13	2023

Other Publications

Article	Year
Summary of the 2016 American Association for Cancer Research (AACR) Annual Meeting. Gynecologic oncology\| PubMed ID: 27181388	2016
AXL modulates extracellular matrix protein expression and is essential for invasion and metastasis in endometrial cancer. Oncotarget\| PubMed ID: 27764792	2016
Therapeutic Inhibition of the Receptor Tyrosine Kinase AXL Improves Sensitivity to Platinum and Taxane in Ovarian Cancer. Molecular cancer therapeutics\| PubMed ID: 30478151	2019
[Not Available]. Gynecologic oncology reports\| PubMed ID: 30582746	2019
p5RHH nanoparticle-mediated delivery of AXL siRNA inhibits metastasis of ovarian and uterine cancer cells in mouse xenografts. Scientific reports\| PubMed ID: 30886159	2019
Differences in presentation and survival of Asians compared to Caucasians with ovarian cancer: An NRG Oncology/GOG Ancillary study of 7914 patients. Gynecologic oncology\| PubMed ID: 31229298	2019
Proteogenomic Characterization of Endometrial Carcinoma. Cell\| PubMed ID: 32059776	2020
FIGO 2018 staging criteria for cervical cancer: Impact on stage migration and survival. Gynecologic oncology\| PubMed ID: 32248993	2020
Homologous recombination deficiency real-time clinical assays, ready or not? Gynecologic oncology\| PubMed ID: 32967790	2020
Obese endometrial cancer survivors' perceptions of weight loss strategies and characteristics that may influence participation in behavioral interventions. Gynecologic oncology reports\| PubMed ID: 33665293	2021
Entinostat, a selective HDAC1/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer. Gynecologic oncology\| PubMed ID: 33867143	2021
Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidatesfor targeted treatment. Nature communications\| PubMed ID: 34429404	2021
Phase 1b study of AVB-500 in combination with paclitaxel or pegylated liposomal doxorubicin platinum-resistant recurrent ovarian cancer. Gynecologic oncology\| PubMed ID: 34474927	2021
GAS6/AXL Inhibition Enhances Ovarian Cancer Sensitivity to Chemotherapy and PARP Inhibition through Increased DNA Damage and Enhanced Replication Stress. Molecular cancer research : MCR\| PubMed ID: 34670865	2022
Culturing Primary Human Mesothelial Cells. Methods in molecular biology (Clifton, N.J.)\| PubMed ID: 34918292	2022
Author Correction: Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment. Nature communications\| PubMed ID: 34996889	2022
Ridiculously good writing: How to write like a pro and publish like a boss. Gynecologic oncology reports\| PubMed ID: 35719321	2022

Copyright © 2026 MyJoVE Corporation. All rights reserved.